Now we may be able to live a healthier and longer life, thanks to the class of drugs that scientists have recently discovered.
The new class of drugs, identified by the Scripps Research Institute (TSRI), Mayo Clinic and other institutions, and have been termed "senolytics," dramatically slow the aging process, alleviate symptoms of weakness, improve cardiac function, hence extending a healthy lifespan in animal models.
Lead researcher, Professor Paul Robbins, PhD, said that they consider the study to be the first big step toward developing treatments that can be given safely to patients to extend healthspan or to treat age-related diseases and disorders.
Senior author, Professor James Kirkland, MD, PhD added that the prototypes of the senolytic agents have more than proven their ability to alleviate multiple characteristics associated with aging. It may eventually become feasible to delay, prevent, alleviate or even reverse multiple chronic diseases and disabilities as a group, instead of just one at a time.
Senescent cells-cells that have stopped dividing-accumulate with age and accelerate the aging process. Since the "healthspan" in mice is enhanced by killing off these cells, the scientists reasoned that finding treatments that accomplish this in humans could have tremendous potential.
The authors caution that more testing was needed before it was used in humans. They also note both drugs in the study have possible side effects, at least with long-term treatment.
The research is published online by the journal Aging Cell.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
